Floatz logo

RIFALDAZINE

Metastatic Melanoma, BRAF V600 Mutation Positive

Genentech, Inc.Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

104 Active assets in the Metastatic Melanoma, BRAF V600 Mutation Positive cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 2BBB
DACARBAZINE
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
TIL
East Metropolitan Health Service, Australia
Phase 2BB

View all 50 →

Same molecule, other indications

RIFALDAZINE is also rated in:

methicillin-resistant staphylococcus aureus infectious diseaseDormant
BB
Indicative ·
71 / 100
View asset →
cystic fibrosisDormant
BB
Indicative ·
65 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →